A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

Timeline

Start

2026-01-23

Primary completion

2028-12-31

Completion

2029-03-31

Drugs

Indications